Former Searle CEO Richard De Schutter is named DuPont Pharmaceuticals chairman. De Schutter was appointed chief administrative officer of Pharmacia when Monsanto merged with Pharmacia & Upjohn in April, and his retirement from the newly merged company was announced in May. Pharmacia said no plans have been made for a replacement. The position of chairman has been vacant since former DuPont Pharmaceuticals Chairman & CEO Kurt Landgraf left the company in May. Nicholas Teti was named new CEO. Teti and De Schutter report to DuPont Chairman Charles Holiday
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
US FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.
A new EU strategy to ensure access to essential medicines will boost the development of critical medical counter measures, including vaccines and therapies, according to one pharmaceutical industry group.
In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.
